EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies

Randall L Morrison iD, Jaskaran Singh, Ella Daly, Maggie Fedgchin, Rachel Ochs-Ross, Keith Karcher, Rosanne Lane, Kim Cooper, Gerard Sanacora iD, Paul Maruff, Wayne C Drevets

International Journal of Neuropsychopharmacology · 2024

DOI: 10.1093/ijnp/pyae046 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2024. Verfasst von Randall L Morrison und 10 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, LLC, Titusville, New Jersey, USA. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Ketamine, Nasal Sprays, Antidepressive Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Janssen Research & Development, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While esketamine is effective in treatment-resistant depression (TRD), detailed information about the effect of esketamine on cognition is relatively scarce. This analysis assessed the effect of short-term (3 double-blind [DB] studies: DB1, DB2, and DB4) or long-term maintenance treatment (DB3) with esketamine nasal spray (ESK) compared with a placebo (PBO) combined with active-comparator, on cognition in patients with TRD.

Methods

Patients (DB1/DB2/DB3: [18–64 years, n = 747]; DB4: [65 years or older, n = 137]) with TRD received ESK (DB1/DB2/DB3: 56/84 mg; DB4: 28/56/84 mg) or PBO+newly initiated oral antidepressant (OAD) as per treatment schedules. Cognitive assessments—Cogstate battery and Hopkins Verbal Learning Test-Revised—were administered at baseline, Day 28/early withdrawal, and follow-up visits in DB1/DB2/DB4 and at 12-week intervals in the DB3 maintenance phase. Descriptive statistics were used to analyze ESK effects on cognition with effect sizes and 95% confidence intervals to express the nature and magnitude of treatment effects relative to active-comparator+PBO. Correlation between depression severity (Montgomery-Ǻsberg Depression Rating Scale scores [MADRS]) and cognition was assessed at baseline and endpoint(s).

Results

At baseline, mild-to-moderate impairment in psychomotor function, attention, and memory (working and episodic) were evident. For each DB1/DB2/DB4, group mean performance in Z-scores for ESK+OAD and OAD+PBO groups on all cognitive tests remained similar or slightly improved from baseline at endpoint (Day 28) and follow-up assessments. Similarly, in DB3 (maintenance phase), both groups generally showed improvement in cognitive performance at endpoint(s). Correlations between MADRS scores and performance on the cognitive test battery were small at baseline and endpoint(s).

Conclusions

This analysis did not identify evidence of negative effects on cognition following short-term or long-term maintenance treatment with ESK+OAD in patients with TRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Depressive Disorder, Treatment-ResistantKetamineNasal SpraysAntidepressive AgentsCognitionHumansMiddle AgedAdultMaleFemaleDouble-Blind MethodAdolescentYoung AdultAgedAdministration, Intranasal

Stichwörter der Autor:innen

CognitionCogstate battery testesketaminerandomized controlled trialstreatment-resistant depression

Substanzen

EsketamineKetamineNasal SpraysAntidepressive Agents

Autor:innen und Institutionen

  • Janssen Research & Development, LLC, Titusville, New Jersey, USA.
  • Janssen Research & Development, LLC, San Diego, California, USA.
  • Janssen Research & Development, LLC, Pennington, New Jersey, USA.
  • Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Yale University, New Haven, Connecticut, USA.
  • Cogstate Ltd, Melbourne, Australia.

ORCID-Profile: Randall L Morrison, Gerard Sanacora

Förderung

  • NCATS NIH HHS
  • Janssen Research & Development, LLC

Zitieren

APA

Morrison, R. L., Singh, J., Daly, E., Fedgchin, M., Ochs-Ross, R., Karcher, K., Lane, R., Cooper, K., Sanacora, G., Maruff, P., & Drevets, W. C. (2024). Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae046

Vancouver

Morrison RL, Singh J, Daly E, Fedgchin M, Ochs-Ross R, Karcher K, et al. Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies. International Journal of Neuropsychopharmacology. 2024. doi:10.1093/ijnp/pyae046

BibTeX
@article{Morrison2024,
  author = {Morrison, Randall L and Singh, Jaskaran and Daly, Ella and Fedgchin, Maggie and Ochs-Ross, Rachel and Karcher, Keith and Lane, Rosanne and Cooper, Kim and Sanacora, Gerard and Maruff, Paul and Drevets, Wayne C},
  title = {Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2024},
  doi = {10.1093/ijnp/pyae046}
}
Kostenlos starten →